Transcriptional Profiling of a Selective CREB Binding Protein Bromodomain Inhibitor Highlights Therapeutic Opportunities
Authors:
- 1 December 2015
- journal article
- Published by Elsevier in Chemistry & Biology
- Vol. 22 (12) , 1588-1596
Abstract
No abstract availableKeywords
This publication has 38 references indexed in Scilit:
- Selectivity and Anti-Parkinson’s Potential of Thiadiazolidinone RGS4 InhibitorsACS Chemical Neuroscience, 2015
- Inducible In Vivo Silencing of Brd4 Identifies Potential Toxicities of Sustained BET Protein InhibitionCell Reports, 2014
- p53 in neurodegenerative diseases and brain cancersPharmacology & Therapeutics, 2014
- BET Protein Function Is Required for Inflammation: Brd2 Genetic Disruption and BET Inhibitor JQ1 Impair Mouse Macrophage Inflammatory ResponsesThe Journal of Immunology, 2013
- Target validation using chemical probesNature Chemical Biology, 2013
- Transcript Dynamics of Proinflammatory Genes Revealed by Sequence Analysis of Subcellular RNA FractionsCell, 2012
- BET domain co-regulators in obesity, inflammation and cancerNature Reviews Cancer, 2012
- Causal reasoning on biological networks: interpreting transcriptional changesBioinformatics, 2012
- Fragment-Based Discovery of Bromodomain Inhibitors Part 2: Optimization of Phenylisoxazole SulfonamidesJournal of Medicinal Chemistry, 2012
- A Small Molecule Binding to the Coactivator CREB-Binding Protein Blocks Apoptosis in CardiomyocytesChemistry & Biology, 2011